SCHEMBL1807992

SCHEMBL1807992

NC(=O)c1cc(N)cc(C(N)=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
CYP3A4 P08684 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
PARP1 P09874 6/20 0.43
TSHR P16473 2/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C19 P33261 1/20 0.43
RECQL P46063 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
DHODH Q02127 2/20 0.43
PARP10 Q53GL7 2/20 0.43
FURIN P09958 1/20 0.43
ALDH1A1 P00352 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL9844728 0.97 KDM4E (0.45) KDM4ECYP3A4SMN1; SMN2PARP1TSHR
SCHEMBL890399 0.94 CYP3A4 (0.44) KDM4ECYP3A4SMN1; SMN2PARP1TSHR
Hydrochloric Acid SCHEMBL9563848 0.92 CYP3A4 (0.43) KDM4ECYP3A4SMN1; SMN2PARP1TSHR
SCHEMBL3661752 0.90 DHODH (0.57) KDM4ECYP3A4SMN1; SMN2PARP1TSHR
SCHEMBL4730653 0.88 FURIN (0.45) KDM4ECYP3A4SMN1; SMN2PARP1TSHR
Ammonia Solution, Strong SCHEMBL20551039 0.88 DHODH (0.55) KDM4ECYP3A4SMN1; SMN2PARP1TSHR
SCHEMBL813450 0.87 PARP1 (0.53) CYP3A4SMN1; SMN2PARP1TSHRPOLB
SCHEMBL6093183 0.85 CYP3A4 (0.39) KDM4ECYP3A4SMN1; SMN2PARP1TSHR
SCHEMBL6093788 0.85 CYP3A4 (0.39) KDM4ECYP3A4SMN1; SMN2PARP1TSHR
SCHEMBL6093793 0.85 PARP1 (0.50) KDM4ECYP3A4SMN1; SMN2PARP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006486-B2 Synthesis of N1,N3-bis(2,3-dihydroxypropyl)-5-nitroisophthalamide LIEBEL-FLARSHEIM COMPANY LLC (US) 2015-04-14 US claimed
EP-0484328-B1 PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODO-5-AMINO-ISOPHTHALAMIDE COMPOUNDS MALLINCKRODT INC (US) 1995-06-14 EP claimed
EP-0484328-A1 PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODO-5-AMINO-N-ALKYLISOPHTHALAMIC ACID AND 2,4,6-TRIIODO-5-AMINO-ISOPHTHALAMIDE COMPOUNDS. MALLINCKRODT INC (US) 1992-05-13 EP claimed
US-5013865-A X-ray contrast media, controlled stoichiometry and kinetics MALLINCKRODT, INC. (US) 1991-05-07 US claimed
WO-1991001296-A1 PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODO-5-AMINO-N-ALKYLISOPHTHALAMIC ACID AND 2,4,6-TRIIODO-5-AMINO-ISOPHTHALAMIDE COMPOUNDS MALLINCKRODT, INC. (US) 1991-02-07 WO claimed
US-4288362-A Monoazo pigments containing a quinazo linonylacetoacetanilide coupling component BAYER AKTIENGESELLSCHAFT (DE) 1981-09-08 US claimed
EP-3985001-B1 PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER SERVIER LAB (FR) 2026-04-29 EP disclosed
CN-119731169-A Sodium channel regulator and application thereof 上海汇伦医药股份有限公司 2025-03-28 CN disclosed
CN-118043916-A Insulated wire, wire harness, and method for manufacturing insulated wire 株式会社自动网络技术研究所 2024-05-14 CN disclosed
WO-2024046253-A1 SODIUM CHANNEL REGULATOR AND USE THEREOF 上海汇伦医药股份有限公司 2024-03-07 WO disclosed
US-20240059733-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2024-02-22 US disclosed
US-20230250050-A1 PROCESS FOR THE PREPARATION OF IOPAMIDOL GE HEALTHCARE AS (NO) 2023-08-10 US disclosed
US-11667673-B2 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2023-06-06 US disclosed
US-4288362-A Monoazo pigments containing a quinazo linonylacetoacetanilide coupling component BAYER AKTIENGESELLSCHAFT (DE) 1981-09-08 US disclosed
US-4260540-A SPIN DYEING POLYACRYLONITRILE BAYER AKTIENGESELLSCHAFT (DE) 1981-04-07 US disclosed
US-4246401-A Axomethine pigments BAYER AKTIENGESELLSCHAFT (DE) 1981-01-20 US disclosed
US-4225489-A Heterocyclic azo dyes and pigments containing 4-quinazolinone moieties BAYER AKTIENGESELLSCHAFT (DE) 1980-09-30 US disclosed
US-4154577-A Uniformly disperse dyed water-swellable cellulosic fibers BASF AKTIENGESELLSCHAFT (DE) 1979-05-15 US disclosed
US-4083686-A AZO DYES, WASHFASTNESS, PHOTOSTABILITY, SOLVENT RESISTANCE BASF AKTIENGESELLSCHAFT (DT) 1978-04-11 US disclosed
US-4014863-A LACQUERS, PRINTING INKS, PAINTS BAYER AKTIENGESELLSCHAFT (DT) 1977-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250050-A1 PROCESS FOR THE PREPARATION OF IOPAMIDOL APC, PKD1, ITPA KDM4E 3866/4885CYP3A4 645/4885SMN1; SMN2 4044/4885
US-20240059733-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE IDH1, IDH3B, IDH3A KDM4E 446/4885CYP3A4 2656/4885SMN1; SMN2 261/4885
US-11667673-B2 Therapeutically active compounds and their methods of use IDH1, IDH3B, IDH3A KDM4E 446/4885CYP3A4 2656/4885SMN1; SMN2 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.